Stock AnalizFortrea Holdings Inc. FTRE
Medical Specialities · data as of November 13, 2026
Fortrea Holdings Inc. (FTRE) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $2.7B and net income of -$69M, a net margin of -2.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (1/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 11.5, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 22% below the current price.
Score: 0.8 / 5
Checks passed
- P/FCF below 20
- 3-year free cash flow growth above 10% a year
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.7B | $2.7B | $2.8B | $2.8B | $3.1B |
| Net income | -$69M | -$986M | -$328M | -$25M | $186M | $98M |
| Free cash flow | $169M | $88M | $237M | $128M | $28M | $143M |
| EPS (diluted) | $-0.66 | $-10.81 | $-3.67 | $-0.29 | $2.09 | $1.10 |
| Net margin | -2.6% | -36.2% | -12.2% | -0.9% | 6.6% | 3.2% |
| ROIC | — | -40.7% | -6.2% | 0.7% | 4.3% | 2.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $23.62, 17% above the current price; targets range from $13.50 to $29.00; the consensus rating is “Buy”; expected EPS is $0.86 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Fortrea stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 22% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fortrea pay a dividend?
Not currently.
Is Fortrea a good stock to buy?
We do not give buy or sell advice. Fortrea scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.